Adolor pops in pre-market on FDA approval

Shares of Adolor Corp. (Nasdaq:ADLR) are gaining ground in pre-market trading after the biopharmaceutical company in conjunction with GlaxoSmithKline (NYSE:GSK) said after Tuesday’s close that the U.S. Food and Drug Administration has approved the firms’ Entereg capsules to help patients regain gastrointestinal function earlier following bowel resection surgery.

Postoperative ileus is a condition that affects almost all patients undergoing this type of surgery and can cause significant discomfort in addition to prolonging hospital stays for patients.

Shares of Adolor gained 14%, or $0.73, to $6.10 in pre-market trading. For detailed price information and recent news stories about Adolor, click ADLR.

Postoperative ileus is a condition that affects almost all patients undergoing this type of surgery and can cause significant discomfort in addition to prolonging hospital stays for patients.

Shares of Adolor gained 14%, or $0.73, to $6.10 in pre-market trading. For detailed price information and recent news stories about Adolor, click ADLR.

For access to the full article, you must be a registered member - it's FREE.

Already a member? Please log in below